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Although p53 deﬁnes cellular responses to cancer treatment it is not clear how p53 can be used to control cell fate
outcome. Data demonstrate that so-called p53 does not exist as a single protein, but is in fact a group of p53 protein
isoforms whose expression can be manipulated to control the cellular response to treatment.
TP53 is the most frequently mutated
gene in human cancers and is thus one of
the most studied (72,500 publications,
pubmed August 2014). For 25 years it
was thought that human TP53 expressed
only one protein, p53. In 2005, we
reported that the human TP53 gene
expresses at least 12 p53 proteins (p53 iso-
forms) as a result of alternative splicing,
alternative initiation of translation, and
alternative promoter usage.1 Each p53 iso-
form contains distinct protein domains.
These p53 isoforms were also identified in
mouse, zebrafish, and Drosophila, suggest-
ing that they play important physiological
roles since their expression is conserved
through evolution. In normal tissue the
human TP53 gene expresses the following
isoforms in a tissue-dependent manner:
p53a (canonical p53), p53b, p53g,
D40p53a, D40p53b, D40p53g,
D133p53a, D133p53b, D133p53g,
D160p53a, D160p53b, and D160p53g.
Only p53a is expressed in every tissue.
However, p53a is never expressed alone;
rather, several p53 isoforms are always co-
expressed with p53a in normal human tis-
sue.1 We and others have analyzed p53
isoform expression in a large panel of can-
cer cell lines and normal cells derived
from diverse tissue origins. None of the
normal and cancer cell lines (epithelial or
fibroblast) expressed only canonical p53
(p53a) and p53a was always co-expressed
with several p53 protein isoforms at the
cellular level.1-7
A large body of evidence has now dem-
onstrated that any changes in cell homeo-
stasis activate a cellular response
dependent on p53. Therefore, any anti-
cancer drugs or treatments that affect cell
homeostasis directly or indirectly activate
p53 and trigger a p53-dependent cell
response. In other words, the expression
of wild-type (WT) TP53 gene determines
whether a cell is going to survive, senesce,
proliferate, differentiate, migrate, or die in
response to cancer treatment. However,
what is the so-called p53 protein? Is p53
only one protein (p53a) or a group of
p53 isoforms? Which protein(s) encoded
by the TP53 gene have the biological and
biochemical activities attributed to p53?
These questions are of paramount impor-
tance because the answers will have a pro-
found impact on the treatment of cancer
patients.
In a recently published article entitled
“Modulation of p53b and p53g expres-
sion by regulating the alternative splicing
of TP53 gene modifies cellular response,”8
we investigated whether p53 is a single
protein, p53a, or a group of p53 protein
isoforms including p53a. We determined
that endogenous p53b and p53g protein
expression can be induced by manipulat-
ing the alternative splicing process. To
achieve this, we treated a panel of WT
TP53 cell lines with a novel specific inhib-
itor of Cdc2-like kinases, TG003. Cdc2-
like kinases regulate some alternative
splicing pre-mRNA processes by
phosphorylating particular splicing factors
such as SRSF1 and SRSF3. Importantly,
inhibition of Cdc2-like kinases does not
abolish all alternative splicing events.
We determined that inhibition of
Cdc2-like kinases by TG003 or the
knockdown of SRSF1 promotes the inclu-
sion of TP53 exons 9b/9g and induces
p53b and p53g protein expression. Using
siRNA that specifically targeted TP53
exons 9b/9g with no effect on p53a
expression, we established that endoge-
nous p53b and p53g inhibit cell prolifera-
tion by promoting cell death in MCF7
cells grown under standard culture condi-
tion. Conversely, by combining TG003
and siRNA targeting specifically TP53
exons 9b/9g with no effect on p53a
expression, we showed that endogenous
p53b and p53g proteins promote prolif-
eration of MCF7 cells upon inhibition of
Cdc2-like kinases by TG003. Therefore,
p53b and p53g have dual activities, pro-
moting either death or proliferation of
WT TP53 cells depending on the cellular
context. Mechanistically, p53b and p53g
form stable protein complexes with p53a
on the DNA of p53-responsive promoters
such that oligomers composed of p53b
and p53a and oligomers composed of
p53g and p53a regulate expression of dif-
ferent p53-responsive genes. The opposite
activities of p53b and p53g isoforms
observed in non-treated and TG003-
treated cells may reflect the effect of
TG003 on both the expression and
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AUTHOR'S VIEW
post-translational modifications of p53
isoforms, which might alter their oligo-
merization abilities.
Our data demonstrate that manipula-
tion of endogenous p53b and p53g pro-
tein expression using a splicing factor
inhibitor and/or siRNA targeting specifi-
cally TP53 exons 9b/9g, allows us to trig-
ger different p53-mediated cell responses
in a single cell line in a controlled way.
This is consistent with previous data; we
and others have previously shown that
D40p53a and D133p53a oligomerize
with p53a and regulate the p53-mediated
cell response.7
For the past 10 years, we and others
have investigated whether p53 is a single
protein, p53a, or a group of p53 isoforms
using different animal models (zebrafish,
Drosophila, mouse) and different normal
and cancer cell lines derived from distinct
human tissues. Irrespective of the cell lines
or animal models used, all of the data con-
sistently indicate that the cell fate decision
in response to damage or cell signals is
defined by the p53 isoforms.6-10 There-
fore, we can now assert that the protein
generally called p53 is NOT a single pro-
tein, p53a, but is in fact an ensemble of
different oligomers, each composed of dis-
tinct p53 protein isoforms. Each oligomer
has a different intrinsic transcriptional
activity and promoter specificity. Hence,
the p53-mediated cell response would be
defined by the sum of the activities of each
p53 isoform oligomer. This would explain
why manipulation of the cellular composi-
tion of p53 isoforms by small molecules
can trigger opposite p53-dependent cell
fate outcomes (repair/survival/prolifera-
tion or cell death) in the same cell type in
response to the same treatment. It is thus
imperative to decipher the mechanism of
p53-isoform mediated cell fate decisions
for efficient clinical application of antican-
cer drugs including the new p53-targeting
drugs such as Nutlin, Prima, and Rita.
In light of the literature discussed here,
p53 isoforms offer novel exciting perspec-
tives in basic and translational research
that I am convinced will revolutionize
cancer treatment, improving patient qual-
ity of life and survival.
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